Compare Crispr Therapeutics AG (CRSP) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Riot Platforms Inc — how do they compare? Crispr Therapeutics AG trades at $53.68 (market cap $4.88B), while Riot Platforms Inc trades at $16.86 (market cap $6.32B). The key difference: Riot Platforms Inc is the larger of the two by market cap, and Riot Platforms Inc is more actively traded (30,571,756 versus 2,861,747). Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Riot Platforms Inc for 16 Days on average.
| CRSP | RIOT | |
|---|---|---|
Market Cap | $4.88B | $6.32B |
Volume | 2,861,747 | 30,571,756 |
Sector | Health | Financials |
52-Week High | $74.92 | $28.67 |
52-Week Low | $44.34 | $11.83 |
Typical Hold Time | 77 Days | 16 Days |
Enterprise Value | $3.30B | $6.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
RIOT stock trades at $16.95, down 8.58% over 24 hours, reflecting bearish technical signals despite a bullish analyst consensus. The company reported a net loss of $663.18 million in 2025, with negative profit margins and cash flow, but is pivoting to AI data center leasing with $9.8 billion in contracted revenue through 2048, per Seeking Alpha on 2026-10-01.
The outlook hinges on execution of the AI strategy, offering significant upside to the $31.64 consensus price target, but high execution risk and persistent losses pose threats to near-term shareholder value amid volatile market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
